Like cAMP, cGMP is now established as an important second messenger that modulates a wide variety of physiological processes. In contrast to the cAMP system, there are multiple cGMP receptors in mammalian cells. These include cGMP-binding phosphodiesterases, cGMP-dependent protein kinases, cGMP-gated ion channels, and perhaps cAMP-dependent protein kinases through """"""""cross-activation"""""""" by cGMP. The long term objective of this investigation will be to determine the mechanism of action and cellular regulation of a cGMP-binding cGMP-specific phosphodiesterase. This enzyme is closely related to the phosphodiesterases of the visual system. cGMP is the second messenger for vision, and the visual phosphodiesterase is the responsive enzyme in this cascade. cGMP may also be involved in neural functions such as memory. cGMP also mediates smooth muscle relaxation caused by agonists such as atrial natriuretic peptide, nitric oxide, and possibly effects of the newly discovered guanylin peptides. Therapeutic or pathological agents that act through cGMP include nitrovasodilators (e.g., nitroglycerin), methylxanthines (e.g., caffeine), and some enterotoxins that cause secretory diarrhea. Agents that elevate cGMP are commonly used for relief of chest pain, asthma, male impotence, and high blood pressure. cGMP-binding cGMP-specific phosphodiesterase will be overexpressed in COS- cells, E. coli, or SF9/baculovirus. Site-directed mutagenesis and a synthetic peptide will be used to study a leucine zipper motif that may provide for dimerization of the enzyme. Using native and recombinant enzyme, a recently discovered Zn2+-binding component, conserved in phosphodiesterase catalytic domains, will be studied using atomic absorption spectrometry, 65Zn2+ binding, mutagenesis, and synthetic peptides. Site-directed mutagenesis will be done on the cGMP-binding sites of the enzyme to determine elements and function for cGMP binding. Analogs specific for cGMP binding and catalytic sites will also be used to study binding site functions. Functional changes of the phosphodiesterase will be measured after phosphorylation by protein kinases and after dephosphorylation by phosphoprotein phosphatases. Phosphorylation of the phosphodiesterase will also be examined by studying 32p incorporation into this enzyme in intact cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM041269-06
Application #
2180754
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1989-07-01
Project End
1998-06-30
Budget Start
1994-07-01
Budget End
1995-06-30
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Physiology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Francis, S H; Turko, I V; Corbin, J D (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
Francis, S H; Turko, I V; Grimes, K A et al. (2000) Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. Biochemistry 39:9591-6
Fink, T L; Francis, S H; Beasley, A et al. (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 274:34613-20
Corbin, J D; Francis, S H (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-32
Turko, I V; Ballard, S A; Francis, S H et al. (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56:124-30
Turko, I V; Francis, S H; Corbin, J D (1998) Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 273:6460-6
Corbin, J D; Beasley, A; Turko, I V et al. (1998) A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5). Cell Biochem Biophys 29:145-57
Francis, S H; Chu, D M; Thomas, M K et al. (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14:81-92
Turko, I V; Francis, S H; Corbin, J D (1998) Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329 ( Pt 3):505-10
Loughney, K; Hill, T R; Florio, V A et al. (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 216:139-47

Showing the most recent 10 out of 25 publications